ACTRN12623000292673招募中2 期
A multi-centre Phase 2 study exploring optimal dosing and scheduling of cyclophosphamide in systemic sclerosis patients undergoing haematopoietic stem cell transplantation.
St Vincent's Hospital, Sydney0 个研究点目标入组 40 人开始时间: 2023年3月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 16 Years 至 70 Years（—）
- 性别
- All
入选标准
- •For those patients who will receive standard dose regimens (200mg/kg cyclophosphamide):
- •Able to provide informed written consent
- •2013 ACR/EULAR classification criteria for SSc
- •Disease duration is 5 years from first non-Raynaud’s manifestation
- •Progressive interstitial lung disease [ILD] (ILD defined as typical findings on a HRCT chest as determined by a radiologist, with greater than 10% of lung involvement) – where progression is defined between two timepoints as a relative FVC decline of 10%, or a relative FVC decline of 5–9% in association with a DLCO relative decline of 15%, or radiological progression on HRCT
- •mRSS is equal to 15 with dSSc skin pattern and progression over the previous 3-12 months of greater than 25% and 5 mRSS points
- •Patient has trialled 3-6 months of highly active therapy at discretion of local site (for example, but not limited to: MMF, rituximab, nintedanib, tocilizumab, cyclophosphamide, methotrexate, azathioprine)
- •Age 16-49
- •Karnofsky grade greater than 60%.
- •Negative serology for HIV.
- •If hepatitis B +ve - willing to take entacavir for 1 year
- •If hepatitis C +ve - must be cleared by anti-viral therapy prior to HSCT
- •Negative pregnancy test.
- •Absence of severe chronic infection.
- •Sperm collection or ova cryopreservation is to be offered prior to HSCT in those of child-bearing age.
- •Cardiac LV Ejection Fraction greater than 50%
- •Resting mean pulmonary artery pressure (mPAP) equal to 20mmHg
- •mPAP less than 30mm/hg after 500mls bolus
- •DLCO equal to 40%.
- •Normal Cardiac MRI
- •For those patients who will receive a low dose conditioning with cyclophosphamide 100mg-140mg/kg with/without rituximab:
- •Able to provide informed written consent
- •2013 ACR/EULAR classification criteria for SSc
- •Disease duration of 5 years from first non-Raynaud’s manifestation
- •Progressive interstitial lung disease [ILD] (ILD defined as typical findings on a HRCT chest as determined by a radiologist, with greater than 10% of lung involvement) – where progression is defined between two timepoints as a relative FVC decline of 10%, or a relative FVC decline of 5–9% in association with a DLCO relative decline of 15%, or radiological progression on HRCT
- •mRSS equal to 15 with dSSc skin pattern and progression over the previous 3-12 months of greater than 25% and 5 mRSS points
- •Patient has trialled 3-6 months of highly active therapy at discretion of local site (for example, but not limited to: MMF, rituximab, nintedanib, tocilizumab, cyclophosphamide, methotrexate, azathioprine)
- •Age 50-70 or less than 50 yrs with poor Karnofsky or cardio-respiratory compromise (as per below).
- •Karnofsky grade greater than 40%
- •Negative serology for HIV.
- •If hepatitis B +ve - willing to take entecavir for 1 year
- •If hepatitis C +ve – must be cleared by anti-viral therapy prior to HSCT
- •Negative pregnancy test.
- •Absence of severe chronic infection.
- •Sperm collection or ova cryopreservation is to be offered prior to HSCT in those of child-bearing age.
- •Ineligible for 200mg/kg cyclophosphamide due to:
- •oCardiac LV Ejection Fraction less than 50%
- •oResting Pulmonary arterial systolic pressure (PASP) greater than 40mmHg or greater than 45mmHg after 500mls bolus
- •oResting Mean pulmonary arterial pressure (mPAP) greater than 20 mmHg or mPAP greater than 30mmHg after 500mls bolus
- •oDecrease or lack of augmentation of CO after fluid challenge
排除标准
- •All patients
- •Karnofsky 30% or less
- •Left ventricular ejection fraction less than 40%
- •Constrictive pericarditis or cardiac tamponade
- •Uncontrolled severe arrhythmia
- •Unstable or severe unrevascularised coronary artery disease
- •Pulmonary arterial systolic pressure (PASP) greater than 60mmHg
- •Mean pulmonary arterial pressure (mPAP) greater than 40mmHg at rest or mPAP greater than 50mmHg with 500mL fluid bolus
- •Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) less than 30%
- •Respiratory failure as defined in the endpoints (use of continuous oxygen or partial pressure of oxygen (pO2) less than 60 mmHg or partial pressure of carbon dioxide (pCO2) greater than 50mmHg without oxygen)
- •Unwilling to cease smoking permanently prior to mobilisation for at least 12 weeks
- •Prior history of malignancy or other current medical condition which in the opinion of the investigators would restrict the ability of the patient to tolerate the procedure.
- •Unable to provide informed consent and/or the diagnosis of mental and cognitive deficits which can interfere with the capability of providing the informed consent.
- •Major bone marrow failure or condition (such as myelodysplasia) which results in significant neutropenia (less than 1000/ul) or thrombocytopenia (less than 100,000/ul).
- •Severe renal disease creatinine clearance less than 40mL/min (measured or estimated)
- •Severe liver disease (Bilirubin greater 50umol/l or known cirrhosis)
- •Gastric antral vascular ectasia (GAVE) with active bleeding ( For inclusion, patients with GAVE must have treated disease eg with argon laser and have no active bleeding). Immediate pre-conditioning endoscopy should be considered in those with a history of GAVE or anaemia/iron deficiency.
- •Gut involvement with systemic sclerosis resulting in malabsorption, chronic diarrhoea or low BMI (less than 20) which in the opinion of the investigators would restrict the ability of the patient to tolerate the procedure
- •Uncontrolled infection.
研究者
相似试验
进行中（未招募）
不适用
Multi-centre, phase II, single arm study of the docetaxel, oxaliplatin, capecitabine (DOC) combination in untreated patients with advanced or metastatic gastric cancerEUCTR2011-001720-37-ITCENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
招募中
2 期
Multicenter Phase 2 Study to Identify the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo) and Personalized Response-driven Adjuvant Combination (PRADO extension cohort)melanoma10040900skin cancerNL-OMON50672ederlands Kanker Instituut80
进行中（未招募）
1 期
A study to find the best combination of ipilimumab and nivolumab before surgeryEUCTR2016-001984-35-SEAntoni van leeuwenhoek ziekenhuis90
进行中（未招募）
1 期
A study to compare the safety of three different combination schemes of immunotherapy drugs (ipilimumab + nivolumab) given to patients who are recently diagnosed with melanoma, before they undergo surgery.EUCTR2016-001984-35-GBAntoni van Leeuwenhoek Hospital90
进行中（未招募）
1 期
A study to find the best combination of ipilimumab and nivolumab before surgeryEUCTR2016-001984-35-ATAntoni van leeuwenhoek ziekenhuis90